193 related articles for article (PubMed ID: 37883072)
1. Tumor Mutational Burden Testing in Solid Tumors.
Kwon R; Cheng HH; Pritchard CC
JAMA Oncol; 2023 Dec; 9(12):1725-1726. PubMed ID: 37883072
[TBL] [Abstract][Full Text] [Related]
2. Association of JAK2-V617F Mutations Detected by Solid Tumor Sequencing With Coexistent Myeloproliferative Neoplasms.
Riedlinger G; Hadigol M; Khiabanian H; Ganesan S
JAMA Oncol; 2019 Feb; 5(2):265-267. PubMed ID: 30605212
[TBL] [Abstract][Full Text] [Related]
3. Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias.
Ma W; Kantarjian H; Zhang X; Yeh CH; Zhang ZJ; Verstovsek S; Albitar M
J Mol Diagn; 2009 Jan; 11(1):49-53. PubMed ID: 19074595
[TBL] [Abstract][Full Text] [Related]
4. Referral centre variation in requesting JAK2 V617F mutation analysis for the investigation of a myeloproliferative neoplasm.
Langabeer SE
J Clin Pathol; 2012 Dec; 65(12):1149-50. PubMed ID: 22872706
[No Abstract] [Full Text] [Related]
5. The Janus kinase 2 (JAK2) V617F mutation in Chinese patients with chronic myeloproliferative disorders.
Xiao Z; Zhang Y; Li L; Nie L; Yang L; Xu S
Haematologica; 2008 May; 93(5):787-8. PubMed ID: 18450736
[No Abstract] [Full Text] [Related]
6. Correlation of JAK2 V617F mutant allele quantitation with clinical presentation and type of chronic myeloproliferative neoplasm.
Malysz J; Crisan D
Ann Clin Lab Sci; 2009; 39(4):345-50. PubMed ID: 19880761
[TBL] [Abstract][Full Text] [Related]
7. A novel germline JAK2 mutation in familial myeloproliferative neoplasms.
Rumi E; Harutyunyan AS; Casetti I; Pietra D; Nivarthi H; Moriggl R; Cleary C; Bagienski K; Astori C; Bellini M; Berg T; Passamonti F; Kralovics R; Cazzola M
Am J Hematol; 2014 Jan; 89(1):117-8. PubMed ID: 24142793
[No Abstract] [Full Text] [Related]
8. Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory.
Agarwal R; Blombery P; McBean M; Jones K; Fellowes A; Doig K; Forsyth C; Westerman DA
Ann Hematol; 2017 May; 96(5):725-732. PubMed ID: 28161773
[TBL] [Abstract][Full Text] [Related]
9. The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms.
Smith CA; Fan G
Hum Pathol; 2008 Jun; 39(6):795-810. PubMed ID: 18538168
[TBL] [Abstract][Full Text] [Related]
10. JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms.
Siemiatkowska A; Bieniaszewska M; Hellmann A; Limon J
Leuk Res; 2010 Mar; 34(3):387-9. PubMed ID: 19643476
[TBL] [Abstract][Full Text] [Related]
11. [JAK2 mutation and thrombosis - recommendations for screening].
Held M
Dtsch Med Wochenschr; 2012 Feb; 137(5):227. PubMed ID: 22278696
[No Abstract] [Full Text] [Related]
12. Effect of mutation order on myeloproliferative neoplasms.
Ortmann CA; Kent DG; Nangalia J; Silber Y; Wedge DC; Grinfeld J; Baxter EJ; Massie CE; Papaemmanuil E; Menon S; Godfrey AL; Dimitropoulou D; Guglielmelli P; Bellosillo B; Besses C; Döhner K; Harrison CN; Vassiliou GS; Vannucchi A; Campbell PJ; Green AR
N Engl J Med; 2015 Feb; 372(7):601-612. PubMed ID: 25671252
[TBL] [Abstract][Full Text] [Related]
13. Splenomegaly and the JAK2 V617F mutation.
Langabeer SE
Eur J Intern Med; 2017 Jan; 37():e45-e46. PubMed ID: 27727073
[No Abstract] [Full Text] [Related]
14. Next-generation sequencing for JAK2 mutation testing: advantages and pitfalls.
Maslah N; Verger E; Schlageter MH; Miclea JM; Kiladjian JJ; Giraudier S; Chomienne C; Cassinat B
Ann Hematol; 2019 Jan; 98(1):111-118. PubMed ID: 30259120
[TBL] [Abstract][Full Text] [Related]
15. Rapid detection of JAK2 V617F mutation using high-resolution melting analysis with LightScanner platform.
Qian J; Lin J; Yao DM; Chen Q; Xiao GF; Ji RB; Li Y; Yang J; Qian Z
Clin Chim Acta; 2010 Dec; 411(23-24):2097-100. PubMed ID: 20728437
[TBL] [Abstract][Full Text] [Related]
16. Mutational status of myeloproliferative neoplasms.
Rumi E; Elena C; Passamonti F
Crit Rev Eukaryot Gene Expr; 2010; 20(1):61-76. PubMed ID: 20528738
[TBL] [Abstract][Full Text] [Related]
17. Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: a report of the Association for Molecular Pathology.
Gong JZ; Cook JR; Greiner TC; Hedvat C; Hill CE; Lim MS; Longtine JA; Sabath D; Wang YL;
J Mol Diagn; 2013 Nov; 15(6):733-44. PubMed ID: 23978506
[TBL] [Abstract][Full Text] [Related]
18. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
19. Underlying mechanisms of the JAK2V617F mutation in the pathogenesis of myeloproliferative neoplasms.
Mullally A
Pathologe; 2016 Nov; 37(Suppl 2):175-179. PubMed ID: 27796499
[TBL] [Abstract][Full Text] [Related]
20. Clinical Implications of Quantitative JAK2 V617F Analysis using Droplet Digital PCR in Myeloproliferative Neoplasms.
Lee E; Lee KJ; Park H; Chung JY; Lee MN; Chang MH; Yoo J; Lee H; Kong SY; Eom HS
Ann Lab Med; 2018 Mar; 38(2):147-154. PubMed ID: 29214759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
